2197 — Clover Biopharmaceuticals Share News
0.000.00%
Last trade - 00:00- HK$1.52bn
- HK$1.40bn
- CNY3.51m
Brief: Clover Biopharmaceuticals Posts FY Loss Of RMB205.1 MLN
Brief: Clover Announces Positive Phase I Clinical Data For Rsv-Hmpv-Piv3 Combination Vaccines And For Rsv Re-Vaccination In Older Adults
Brief: Clover Biopharmaceuticals Posts H1 Revenue Of RMB3.3 Million
Brief: Clover Biopharmaceuticals Says It Terminates Cooperation With Adimmune
Brief: Clover Biopharmaceuticals Says Gavi Files Arbitration Request Against Clover HK
Brief: Clover Biopharmaceuticals Posts Loss For Year RMB903.4 Million
Brief: Clover Biopharmaceuticals Says Gavi Terminates Advance Purchase Agreement With Clover HK
Brief: Clover Biopharmaceuticals Reports Clearance Of Study For Rsv Vaccine Candidate By FDA
Brief: Clover Biopharmaceuticals Posts FY Loss RMB138.5 Mln
Brief: Clover Announces Positive Phase 1 Results For Scb-219M For Treatment Of Chemotherapy-Induced Thrombocytopenia
Brief: Clover Biopharmaceuticals Says Completes BLA Submission For Seasonal Influenza Vaccine In Brazil
Brief: Clover Biopharmaceuticals Launches Quadrivalent Seasonal Influenza Vaccine In Mainland China
Brief: Clover Biopharmaceuticals Informed By CEO Of His Intention To Increase Holding Of Shares Of Co
Brief: Clover Biopharmaceuticals Plans To License In Mid- To Late-Stage Vaccine Product In H2 Of 2023
Brief: Clover Biopharmaceuticals Sees Net Profit To Be Not Less Than RMB500 Mln For Six-Month
Brief: Clover Biopharmaceuticals Does Not See Meaningful Financial Contribution From Covid Vaccine Sales In 2023
Brief: Clover Biopharmaceuticals Establishes A Commercial Partnership
Brief: Clover Biopharmaceuticals Posts FY Loss Of RMB2.45 Billion
Brief: Clover Biopharmaceuticals Enters Exclusive Agreement With Adimmune Corporation